Capricor Therapeutics Faces Lawsuit and FDA Delay as Stock Plummets

Key Facts

In a move reflecting the regulatory and legal hurdles facing the biotech sector, Capricor Therapeutics has come under intense pressure, leading to a massive decline in its stock value. The company is currently facing a securities class action lawsuit regarding data integrity issues in its HOPE-3 study for Deramiocel, following allegations of unagreed changes to the statistical analysis plan. This revelation severely damaged investor confidence, causing the stock to plummet by 78.70% according to analyst reports.

Adding to the legal turmoil, the U.S. FDA has extended its review period for Deramiocel, pushing the PDUFA target action date to November 22, 2026. Per market data, H.C. Wainwright confirmed its 'Neutral' rating on the stock, citing significant uncertainty after the price was previously noted at $7.09. These developments occur as the market increasingly scrutinizes the clinical trial integrity of emerging pharmaceutical firms.

Looking ahead, Capricor Therapeutics remains under close watch, though current price data is unavailable as of August 24, 2026. The new FDA deadline in November 2026 serves as the primary future catalyst, while investors await further developments regarding the lawsuit covering securities purchased between December 2025 and July 2026. There are no immediate macroeconomic events in the current calendar directly impacting the biotech sector's specific regulatory outlook.